This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Stanford Graduate School of Business (USA)
-
Netflix and the State of Streaming Video in 2011
Feinberg, Yossi; Johnson, ChristyCase SGSB-SM267-EStrategyIn 2010, only 16 percent of Americans were streaming movies and television shows online. By the end of 2011 that number would almost double, and the entertainment industry began barreling towards a digital future. This case follows Netflix, Hulu, Amazon, and HBO through the year 2011 as they launched and improved their streaming video capabilities. Though Netflix had historically been the most popular player in the streaming video market, Hulu, A...Starting at €8.20
-
The Political Economy of Ethanol Policy in the U.S. and Brazil
Casey, Katherine; Johnson, ChristyCase SGSB-P103-EStrategyThis case focuses on the political economy of ethanol policy in the United States and Brazil. The cases outlines policies put in place by the governments of the United States and Brazil to bolster the ethanol industry and the role of politics and interest groups.Starting at €8.20
-
Scoot: Singapore Airlines’ Low-Cost Carrier Strategy
Carroll, Glenn; Sørensen, Jesper; Schifrin, DebraCase SGSB-SM321-EStrategyIn December 2019, Scoot, the low-cost carrier (LCC) launched by Singapore Airlines Limited in 2011, had successfully established itself in the Asian market, having flown over 65 million passengers to 68 destinations with a fleet of 48 aircraft. Scoot accounted for 14 percent of seat capacity in Singapore, and 43 percent of LCC capacity out of the country. In 2016, SIA fully acquired and integrated the local LCC Tigerair into Scoot. Scoot’s gr...Starting at €8.20
-
Arterys
Chess, Robert; Lehman, CameronCase SGSB-SM297-EStrategyFabien Beckers, Founder and CEO of Arterys, walks through the creation of his medical / AI imaging company, including the equity struggles of the founding team, building the right team and final the right channel sales partners.Starting at €8.20
-
Amir Dan Rubin: Success from the Beginning
Pfeffer, JCase SGSB-OB90-ECorporate Governance, StrategyIn November of 2010, the board of Stanford Hospital and Clinics announced that Amir Dan Rubin, at the time chief operating officer of the UCLA Hospital System, would become the next CEO at Stanford Hospital and Clinics. Although by 2010 Stanford hospital had largely recovered from a failed merger with the hospital of the University of California, San Francisco, and was financially stable, Rubin would lead an organization that still faced signifi...Starting at €8.20
-
Landlocked Homes: Catching a Falling Knife
Abbey, D; Mahowald, C; Lamont, MCase SGSB-RE137-EStrategyWhen Jacob Harold became head of the Hewlett Foundation’s Philanthropy Program, he began to see GuideStar as much more than just a website. GuideStar was the result of founder Arthur “Buzz” Schmidt’s vision of bringing transparency and accountability to the world of nonprofits. At its core, the organization compiled information that U.S. nonprofits submitted on their IRS filings into an easy to use database. It supplemented that information wi...Starting at €8.20
-
TTTech (C ): Hitting the Gas Pedal
Siegel RCase SGSB-SM185C-EStrategyTo be used in conjunction with the (A) and (B) cases, keeping the students current on the status of the firm.Starting at €8.20
-
Health Leads (A): Expansion Decisions for a Health Care Nonprofit
Sorensen J; Schifrin D; Hettrich KCase SGSB-SM192A-EStrategyThe (A) case presents a 2009 critical expansion decision for health care nonprofit Health Leads: whether to expand rapidly while it had momentum, strong advocates, very high demand for its services, and funder support for growth; or whether to postpone rapid expansion and continue working on its model and further prove the company’s value to hospitals and clinics. Founded by Rebecca Onie (2009 MacArthur “Genius Grant” Fellow), Health Leads addre...Starting at €8.20
-
Invitrogen (A)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209A-EStrategyFounded in 1987, Invitrogen was one of the largest catalog life science companies in the industry. Its customers came from academic research, biotechnology and pharmaceutical companies and government laboratories. Scientists viewed Invitrogen as a one-stop shop for all major molecular biology, biochemistry and cell culture reagent products, with prices ranging from a hundred dollars to a few thousand dollars.Starting at €8.20
-
Invitrogen/Life Technologies (B)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209B-EStrategyOn June 12, 2008, Invitrogen and Applied Biosystems announced plans to merge. The combined company was to be renamed Life Technologies (NASDAQ: LIFE). Invitrogen offered to acquire Applied Biosystems for $6.7 billion in cash and stock. AB shareholders would receive $38 per share in cash and stock, representing a 17 percent premium over the share’s closing price on Wednesday, June 11, 2008.Starting at €5.74